METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced prostate cancer: experimental combo trial launches
Disease control Recruiting nowThis study tests a new drug (JNJ-78278343) combined with other treatments for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose and to monitor side effects. About 300 participants will be enrolle…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New study monitors Darolutamide's safety in korean prostate cancer patients
Disease control Recruiting nowThis observational study follows 600 Korean men with prostate cancer who are already prescribed darolutamide. The goal is to track side effects and see how well the drug works over one year. Researchers will review medical records during routine doctor visits every 2 to 4 months.
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New prostate cancer drug trial for chinese men
Disease control Recruiting nowThis early-stage study tests a new drug called ASP5541 in about 12 Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to see if the drug is safe and how it is proce…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New radiation therapy aims to shrink tough prostate cancers
Disease control Recruiting nowThis study is for people with metastatic prostate cancer that has spread and is no longer controlled by hormone therapy. It tests a new drug called [212Pb]Pb-ADVC001, which delivers a precise dose of radiation directly to cancer cells. The goal is to find the safest and most effe…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for men with advanced prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding a new drug, JSB462 (luxdegalutamide), to standard hormone therapy (abiraterone) works better than current treatments for men whose prostate cancer has spread and still responds to hormones. About 150 men will receive either the combination or stand…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New shot could replace daily pills for advanced prostate cancer
Disease control Recruiting nowThis study tests a new injectable form of the hormone therapy abiraterone (ASP5541) in men with advanced prostate cancer that has spread. The shot is given every 12 weeks, instead of daily pills. The goal is to see if it works as well as or better than the standard pill, and to c…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Real-World study tracks darolutamide use in advanced prostate cancer
Knowledge-focused Recruiting nowThis study observes how men with metastatic hormone-sensitive prostate cancer (mHSPC) are treated with darolutamide in everyday urology clinics across the US. Researchers will review medical records of about 1,400 patients to understand who gets which treatment (darolutamide with…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Prostate cancer Patients' Pill-Taking habits under the microscope
Knowledge-focused Recruiting nowThis study tracks 270 men with advanced prostate cancer that has spread but still responds to hormone therapy. Researchers want to see how faithfully patients take their apalutamide pills over the first year. The goal is to understand which patients might struggle with adherence …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen Cilag S.A.S. • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC